17α-羟孕酮己酸酯与妊娠期糖耐量异常风险:系统综述与Meta分析
该系统综述与Meta分析检索至2018年10月的多个数据库,纳入6项研究(其中4项为队列研究),比较有自发性早产史的单胎妊娠妇女使用17α-羟孕酮己酸酯与未暴露对照组。暴露组妊娠期糖尿病(GDM)发生率为10.9%,对照组为6.1%(RR 1.77,95%CI 1.22-2.55);排除队列研究后,随机分配至17α-羟孕酮己酸酯的妇女中效应估计无统计学意义(RR 1.21,95%CI 0.63-2.36)。
要点
- 6项研究共5053名妇女,暴露组GDM发生率10.9%,对照组6.1%(RR 1.77,95%CI 1.22-2.55)。
- 排除队列研究后,随机分配组的效应估计无统计学意义(RR 1.21,95%CI 0.63-2.36)。
- 有自发性早产史的单胎妊娠妇女每周使用17α-羟孕酮己酸酯者异常血糖筛查结果和GDM发生率更高。
核心结论
- 有自发性早产史的单胎妊娠妇女每周使用17α-羟孕酮己酸酯预防早产,其异常血糖检测结果和GDM发生率显著高于未暴露对照组,但该发现在随机分配至17α-羟孕酮己酸酯的妇女中未成立。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Scopus、ClinicalTrials.gov、PROSPERO、EMBASE、Scielo和Cochrane对照试验中心注册库至2018年10月前发表的研究。
- 纳入比较17α-羟孕酮己酸酯与未暴露对照组、有自发性早产史的单胎妊娠妇女的研究,最终纳入6项研究(其中4项为队列研究),共5053名妇女。
- 暴露组1538名(30.4%)接受17α-羟孕酮己酸酯,未暴露对照组3515名(69.6%);采用DerSimonian and Laird随机效应模型进行Meta分析。
主要发现
- 暴露组GDM总体发生率为10.9%,未暴露对照组为6.1%(RR 1.77,95%CI 1.22-2.55)。
- 排除队列研究后,随机分配至17α-羟孕酮己酸酯的妇女中效应估计无统计学意义(RR 1.21,95%CI 0.63-2.36)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether 17α-hydroxyprogesterone caproate use in preventing preterm birth increases the risk of gestational diabetes mellitus (GDM). DATA SOURCES: Electronic databases (MEDLINE, Scopus, ClinicalTrials.gov, PROSPERO, EMBASE, Scielo and the Cochrane Central Register of Controlled Trials) were searched for studies published before October 2018. Keywords included "gestational diabetes," "preterm birth," "pregnancy," and "17-hydroxyprogesterone caproate." METHODS OF STUDY SELECTION: Studies comparing 17α-hydroxyprogesterone caproate with unexposed control groups in women with singleton gestation and a history of a prior spontaneous preterm birth were included. The primary outcome was the development of GDM. Secondary outcomes included abnormal 1-hour, 50-g glucose screen results and mean venous blood glucose levels. Summary estimates were reported as mean differences and 95% CI for continuous variables or relative risk (RR) with 95% CI for dichotomous outcomes. Meta-analysis was performed using the random effects model of DerSimonian and Laird. TABULATION, INTEGRATION AND RESULTS: Six studies, four of which were cohort studies, met inclusion criteria and were included in the final meta-analysis. Of the 5,053 women, 1,538 (30.4%) received 17α-hydroxyprogesterone caproate and 3,515 (69.6%) were in unexposed control groups. The overall rate of GDM in women exposed to 17α-hydroxyprogesterone caproate was 10.9% vs 6.1% in women who were not exposed (RR 1.77, 95% CI 1.22-2.55). After exclusion of the cohort studies, the summary estimate of effect was nonsignificant among women who had been randomly allocated to 17α-hydroxyprogesterone caproate (RR 1.21, 95% CI 0.63-2.36). CONCLUSION: Women with singleton gestations receiving weekly 17α-hydroxyprogesterone caproate for recurrent preterm birth prevention had a significantly higher incidence of abnormal glucose test results and GDM compared with those in unexposed control groups, a finding that did not hold among women who had been randomly allocated to 17α-hydroxyprogesterone caproate. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42016041694.
引用
- Eke AC, Sheffield J, Graham EM, et al. 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis. Obstet Gynecol. 2019. PMID: 30741815. doi:10.1097/AOG.0000000000003115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。